Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial

Teresa L. Kauf, Robert S. Svatek, Gilad Amiel, Timothy L. Beard, Sam S. Chang, Amr Fergany, R. Jeffrey Karnes, Michael Koch, Jerome O'Hara, Cheryl T. Lee, Wade J. Sexton, Joel W. Slaton, Gary D. Steinberg, Shandra S. Wilson, Lee Techner, Carolyn Martin, Jessica Moreno, Ashish M. Kamat

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences

Immunology and Microbiology